Bufalin serves as a pharmaceutic that mitigates drug resistance

References

• Burris HA. 3rd. 2013. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 71(4):829–842.
   PubMed Web of Science ®Google Scholar
• Carneiro BA, El-Deiry WS. 2020. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 17(7):395–417.
   PubMed Web of Science ®Google Scholar
• Chang Y, Zhao Y, Gu W, Cao Y, Wang S, Pang J, Shi Y. 2015. Bufalin inhibits the differentiation and proliferation of cancer stem cells derived from primary osteosarcoma cells through Mir-148a. Cell Physiol Biochem. 36(3):1186–1196.
   PubMed Web of Science ®Google Scholar
• Chang Y, Zhao Y, Zhan H, Wei X, Liu T, Zheng B. 2014. Bufalin inhibits the differentiation and proliferation of human osteosarcoma cell line hMG63-derived cancer stem cells. Tumour Biol. 35(2):1075–1082.
   PubMedGoogle Scholar
• Chen J, Wang H, Jia L, He J, Li Y, Liu H, Wu R, Qiu Y, Zhan Y, Yuan Z, et al. 2021. Bufalin targets the SRC-3/MIF pathway in chemoresistant cells to regulate M2 macrophage polarization in colorectal cancer. Cancer Lett. 513:63–74.
   PubMed Web of Science ®Google Scholar
• Chunyan G, Yajun W, Lulin Z, Li Q, Shanliang S, Miaomiao S, Xiaozhu T, Pinggang D, Chao T, Yuhao C, et al. 2022. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. J Exp Clin Cancer Res. 41:1.
   PubMed Web of Science ®Google Scholar
• Clarke MF. 2019. Clinical and therapeutic implications of cancer stem cells. N Engl J Med. 380(23):2237–2245.
   PubMed Web of Science ®Google Scholar
• Cui Q, Wang JQ, Assaraf YG, Ren L, Gupta P, Wei L, Ashby CR, Jr., Yang DH, Chen ZS. 2018. Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Updat. 41:1–25.
   PubMed Web of Science ®Google Scholar
• Dai XY, Zhou BF, Xie YY, Lou J, Li KQ. 2018. Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells. Oncol Lett. 15(5):8019–8026.
   PubMed Web of Science ®Google Scholar
• Engelman JA. 2009. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 9(8):550–562.
   PubMed Web of Science ®Google Scholar
• Fruehauf JP, Meyskens FL. Jr. 2007. Reactive oxygen species: a breath of life or death? Clin Cancer Res. 13(3):789–794.
   PubMed Web of Science ®Google Scholar
• Fujii E, Inada Y, Kakoki M, Nishimura N, Endo S, Fujiwara S, Wada N, Kawano Y, Okuno Y, Sugimoto T, et al. 2018. Bufalin induces DNA damage response under hypoxic condition in myeloma cells. Oncol Lett. 15(5):6443–6449.
   PubMed Web of Science ®Google Scholar
• Garcia-Mayea Y, Mir C, Masson F, Paciucci R, LLeonart ME. 2020. Insights into new mechanisms and models of cancer stem cell multidrug resistance. J Semin Cancer Biol. 60(prepublish):166–180.
   PubMed Web of Science ®Google Scholar
• Gu W, Liu L, Fang FF, Huang F, Cheng BB, Li B. 2014. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells. Oncol Rep. 31(1):216–222.
   PubMed Web of Science ®Google Scholar
• Guo W, Tan H-Y, Chen F, Wang N, Feng Y. 2020. Targeting cancer metabolism to resensitize chemotherapy: potential development of cancer chemosensitizers from traditional chinese medicines. J Cancers. 12(2):404.
   Web of Science ®Google Scholar
• HanYu C, Chueh F-S, Ma Y-S, Wu RS-C, Liao C-L, Chu Y-L, Fan M-J, Huang W-W, Chung J-G. 2017. Bufalin induced apoptosis in SCC‑4 human tongue cancer cells by decreasing Bcl‑2 and increasing Bax expression via the mitochondria‑dependent pathway. J Molecular Medicine Reports. 16(6):7959–7966.
   PubMed Web of Science ®Google Scholar
• Hongyan Z, Dali Z, Huilin J, Hongwei L, Xiaoying Y, Liwei Z, Tiefu L. 2016. Bufalin reverses intrinsic and acquired drug resistance to cisplatin through the AKT signaling pathway in gastric cancer cells. J Mol Med Rep. 14(2):1817–1822.
   PubMed Web of Science ®Google Scholar
• Hosoi T, Hyoda K, Okuma Y, Nomura Y, Ozawa K. 2007. Akt up- and down-regulation in response to endoplasmic reticulum stress. Brain Res. 1152:27–31.
   PubMed Web of Science ®Google Scholar
• Jia XQ SP. 2017. Research on active ingredients from Cinobufagin and their advances in anti-tumor mechanisms. Liao-ning Chung I Yao Ta Hsueh Hsueh Pao.19(03):215–217.
   Google Scholar
• Kang KH, Han MH, Jeong JW, Park C, Lee SH, Lee HW, Hong SH, Choi YH, Hong SH. 2017. Bufalin sensitizes human bladder carcinoma cells to TRAIL-mediated apoptosis. Oncol Lett. 14(1):853–859.
   PubMed Web of Science ®Google Scholar
• Kang X, Lu P, Cui Y, Wang Y, Zhang Q, Gong Y, Xu Z. 2015. Bufalin reverses hepatocyte growth factor-induced resistance to afatinib in H1975 lung cancer cells. Zhonghua Zhong Liu Za Zhi. 37(7):490–496.
   PubMedGoogle Scholar
• Kang XH, Xu ZY, Gong YB, Wang LF, Wang ZQ, Xu L, Cao F, Liao MJ. 2013. Bufalin reverses HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via blockage of Met/PI3k/Akt pathway and induction of apoptosis. Evid Based Complement Alternat Med. 2013:243859.
   PubMed Web of Science ®Google Scholar
• Kun E, Tsang YTM, Ng CW, Gershenson DM, Wong KK. 2021. MEK inhibitor resistance mechanisms and recent developments in combination trials. Cancer Treat Rev. 92:102137.
   PubMed Web of Science ®Google Scholar
• Kuo JY, Liao CL, Ma YS, Kuo CL, Chen JC, Huang YP, Huang WW, Peng SF, Chung JG. 2022. Combination treatment of Sorafenib and Bufalin induces apoptosis in NCI-H292 human lung cancer cells in vitro. In Vivo. 36(2):582–595.
   PubMed Web of Science ®Google Scholar
• Lan YL, Lou JC, Jiang XW, Wang X, Xing JS, Li S, Zhang B. 2019. A research update on the anticancer effects of bufalin and its derivatives. Oncol Lett. 17(4):3635–3640.
   PubMed Web of Science ®Google Scholar
• Li H, Wang P, Gao Y, Zhu X, Liu L, Cohen L, Meng Z, Yang P. 2011. Na+/K+-ATPase alpha3 mediates sensitivity of hepatocellular carcinoma cells to bufalin. Oncol Rep. 25(3):825–830.
   PubMed Web of Science ®Google Scholar
• Lin Y, Wang Z, Liu L, Chen L. 2011. Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells. J Lung Cancer. 71(3):291–297.
   Google Scholar
• LingHu HR, Luo H, Gang L. 2020. Bufalin induces glioma cell death by apoptosis or necroptosis. Onco Targets Ther. 13:4767–4778.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang Y, Sun S, Zhang G, Jiang K, Sun P, Zhang Y, Yao B, Sui R, Chen Y, et al. 2019. Bufalin induces apoptosis and improves the sensitivity of human glioma stem-like cells to temozolamide. Oncol Res. 27(4):475–486.
   PubMed Web of Science ®Google Scholar
• Liu T, Wu C, Weng G, Zhao Z, He X, Fu C, Sui Z, Huang SX. 2017. Bufalin inhibits cellular proliferation and cancer stem cell-like phenotypes via upregulation of MiR-203 in Glioma. Cell Physiol Biochem. 44(2):671–681.
   PubMedGoogle Scholar
• Liu XD, Song CY, Kong CC, Tian X. 2022. Bufalin induces programmed necroptosis in triple-negative breast cancer drug-resistant cell lines through RIP1/ROS-mediated pathway. Chin J Integr Med. 28(10):900–908.
   PubMed Web of Science ®Google Scholar
• Luo J, Manning BD, Cantley LC. 2003. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 4(4):257–262.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Basecke J, et al. 2011. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol. 226(11):2762–2781.
   PubMed Web of Science ®Google Scholar
• Meng Z, Garrett CR, Shen Y, Liu L, Yang P, Huo Y, Zhao Q, Spelman AR, Ng CS, Chang DZ, et al. 2012. Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. Br J Cancer. 107(3):411–416.
   PubMed Web of Science ®Google Scholar
• Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, et al. 2009. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer. 115(22):5309–5318.
   PubMed Web of Science ®Google Scholar
• Michele M, Italia F, Fabiana C, Silvia MAS, Teresa DL, Chiara B, Vincenzo CMS, Isabella S, et al. 2017. PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. J Sci Rep. 7(1):43013.
   PubMed Web of Science ®Google Scholar
• Nahal H, Lin Y, Travis G, Simpson AM, Nassif NT, McGowan EM. 2018. PTEN/PTENP1: ‘regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy. Mol Cancer. 17(1):3.
   PubMed Web of Science ®Google Scholar
• Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. 2014. MEK in cancer and cancer therapy. Pharmacol Ther. 141(2):160–171.
   PubMed Web of Science ®Google Scholar
• Nooter K, Stoter G. 1996. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract. 192(7):768–780.
   PubMed Web of Science ®Google Scholar
• Peng G, Liu Y. 2015. Hypoxia-inducible factors in cancer stem cells and inflammation. Trends Pharmacol Sci. 36(6):374–383.
   PubMed Web of Science ®Google Scholar
• Qian L, Su H, Wang G, Li B, Shen G, Gao Q. 2020. Anti-tumor activity of Bufalin by inhibiting c-MET mediated MEK/ERK and PI3K/AKT signaling pathways in gallbladder cancer. J Cancer. 11(11):3114–3123.
   PubMed Web of Science ®Google Scholar
• Qin L, Wang Z, Tao L, Wang Y. 2010. ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy. Autophagy. 6(2):239–247.
   PubMed Web of Science ®Google Scholar
• Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP, Pan BR. 2008. Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World J Gastroenterol. 14(33):5210–5216.
   PubMed Web of Science ®Google Scholar
• Ramsey MR, Sharpless NE. 2006. ROS as a tumour suppressor? J Nature Cell Biol. 8(11):1213–1215.
   PubMed Web of Science ®Google Scholar
• Roskoski R. Jr. 2012. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res. 66(2):105–143.
   PubMed Web of Science ®Google Scholar
• Seebacher NA, Krchniakova M, Stacy AE, Skoda J, Jansson PJ. 2021. Tumour microenvironment stress promotes the development of drug resistance. Antioxidants. 10(11):801.
   Web of Science ®Google Scholar
• Soumoy L, Ghanem GE, Saussez S, Journe F. 2022. Bufalin for an innovative therapeutic approach against cancer. Pharmacol Res. 184:106442.
   PubMed Web of Science ®Google Scholar
• Su EY, Chu YL, Chueh FS, Ma YS, Peng SF, Huang WW, Liao CL, Huang AC, Chung JG. 2019. Bufalin induces apoptotic cell death in human nasopharyngeal carcinoma cells through mitochondrial ROS and TRAIL pathways. Am J Chin Med. 47(1):237–257.
   PubMed Web of Science ®Google Scholar
• Su S, Dou H, Wang Z, Zhang Q. 2021. Bufalin inhibits ovarian carcinoma via targeting mTOR/HIF-alpha pathway. Basic Clin Pharmacol Toxicol. 128(2):224–233.
   PubMed Web of Science ®Google Scholar
• Sun J, Xu K, Qiu Y, Gao H, Xu J, Tang Q, Yin P. 2017. Bufalin reverses acquired drug resistance by inhibiting stemness in colorectal cancer cells. Oncol Rep. 38(3):1420–1430.
   PubMed Web of Science ®Google Scholar
• Tan H, Zhang M, Wang Y, Timashev P, Zhang Y, Zhang S, Liang XJ, Li F. 2022. Innovative nanochemotherapy for overcoming cancer multidrug resistance. Nanotechnology. 33(5):052001.
   Web of Science ®Google Scholar
• Tan X, Liang X, Xi J, Guo S, Meng M, Chen X, Li Y. 2021. Clinical efficacy and safety of Huachansu injection combination with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Medicine. 100(36):e27161.
   PubMed Web of Science ®Google Scholar
• Trachootham D, Alexandre J, Huang P. 2009. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 8(7):579–591.
   PubMed Web of Science ®Google Scholar
• Vitiello PP, Cardone C, Martini G, Ciardiello D, Belli V, Matrone N, Barra G, Napolitano S, Della Corte C, Turano M, et al. 2019. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. J Exp Clin Cancer Res. 38(1):41.
   PubMed Web of Science ®Google Scholar
• Wang H, Ning Z, Li Y, Zhu X, Meng Z. 2016. Bufalin suppresses cancer stem-like cells in gemcitabine-resistant pancreatic cancer cells via Hedgehog signaling. Mol Med Rep. 14(3):1907–1914.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen C, Wang S, Zhang Y, Yin P, Gao Z, Xu J, Feng D, Zuo Q, Zhao R, et al. 2015. Bufalin inhibits HCT116 colon cancer cells and its orthotopic xenograft tumor in mice model through genes related to apoptotic and PTEN/AKT pathways. Gastroenterol Res Pract. 2015:457193.
   PubMed Web of Science ®Google Scholar
• Wang J, Xia Y, Zuo Q, Chen T. 2018. Molecular mechanisms underlying the antimetastatic activity of bufalin. Mol Clin Oncol. 8(5):631–636.
   PubMed Web of Science ®Google Scholar
• Wang T, Mu L, Jin H, Zhang P, Wang Y, Ma X, Pan J, Miao J, Yuan Y. 2016. The effects of bufadienolides on HER2 overexpressing breast cancer cells. Tumour Biol. 37(6):7155–7163.
   PubMedGoogle Scholar
• Wang T, Zhang L, Han L, Liu X, Zhang H, Zhang J, Yu H. 2018. Clinical effect of intravenous infusion of zoledronic acid combined with oral medication of cinobufagin in the treatment of metastatic bone tumors. Pak J Pharm Sci. 31(4(Special):1609–1612.
   PubMed Web of Science ®Google Scholar
• Wang Z, Qi F, Cui Y, Zhao L, Sun X, Tang W, Cai P. 2018. An update on Chinese herbal medicines as adjuvant treatment of anticancer therapeutics. Biosci Trends. 12(3):220–239.
   PubMed Web of Science ®Google Scholar
• Wong RS. 2011. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 30(1):87.
   PubMed Web of Science ®Google Scholar
• Wu D, Zhou WY, Lin XT, Fang L, Xie CM. 2019. Bufalin induces apoptosis via mitochondrial ROS-mediated caspase-3 activation in HCT-116 and SW620 human colon cancer cells. Drug Chem Toxicol. 42(4):444–450.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhang D, Ni M, Xue J, Wang K, Duan X, Liu S. 2020. Effectiveness of Huachansu injection combined with chemotherapy for treatment of gastric cancer in China: a systematic review and Meta-analysis. J Tradit Chin Med. 40(5):749–757.
   PubMed Web of Science ®Google Scholar
• Wu T, Sun R, Wang Z, Yang W, Shen S, Zhao Z. 2014. A meta-analysis of Cinobufacini combined with transcatheterarterial chemoembolization in the treatment of advanced hepatocellular carcinoma. J Cancer Res Ther. 10(Suppl 1):60–64.
   PubMed Web of Science ®Google Scholar
• Xiang RF, Wang Y, Zhang N, Xu WB, Cao Y, Tong J, Li JM, Wu YL, Yan H. 2017. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell Death Dis. 8(5):e2776.
   PubMed Web of Science ®Google Scholar
• Yan S, Qu X, Xu C, Zhu Z, Zhang L, Xu L, Song N, Teng Y, Liu Y. 2012. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells. J Cancer Res Clin Oncol. 138(8):1279–1289.
   PubMed Web of Science ®Google Scholar
• Yan S, Qu X, Xu L, Che X, Ma Y, Zhang L, Teng Y, Zou H, Liu Y. 2014. Bufalin enhances TRAIL-induced apoptosis by redistributing death receptors in lipid rafts in breast cancer cells. Anticancer Drugs. 25(6):683–689.
   PubMed Web of Science ®Google Scholar
• Yuan ZT, Shi XJ, Yuan YX, Qiu YY, Zou Y, Liu C, Yu H, He X, Xu K, Yin PH. 2017. Bufalin reverses ABCB1-mediated drug resistance in colorectal cancer. Oncotarget. 8(29):48012–48026.
   PubMedGoogle Scholar
• Yu-Long L, Zou Y-J, Lou J-C, Xing J-S, Wang X, Zou S, Ma B-B, Ding Y, Zhang B. 2019. The sodium pump α1 subunit regulates bufalin sensitivity of human glioblastoma cells through the p53 signaling pathway. Cell Biol Toxicol. 35(6):521–539.
   PubMed Web of Science ®Google Scholar
• Zhai B, Hu F, Yan H, Zhao D, Jin X, Fang T, Pan S, Sun X, Xu L. 2015. Bufalin reverses resistance to sorafenib by inhibiting Akt activation in hepatocellular carcinoma: the role of endoplasmic reticulum stress. PLoS One. 10(9):e0138485.
   PubMed Web of Science ®Google Scholar
• Zhai X, Lu J, Wang Y, Fang F, Li B, Gu W. 2014. Reversal effect of bufalin on multidrug resistance in K562/VCR vincristine-resistant leukemia cell line. J Tradit Chin Med. 34(6):678–683.
   PubMed Web of Science ®Google Scholar
• Zhan Y, Qiu Y, Wang H, Wang Z, Xu J, Fan G, Xu J, Li W, Cao Y, Le V-M, et al. 2020. Bufalin reverses multidrug resistance by regulating stemness through the CD133/nuclear factor-kappaB/MDR1 pathway in colorectal cancer. Cancer Sci. 111(5):1619–1630.
   PubMed Web of Science ®Google Scholar
• Zhou B, Wu F, Yuan L, Miao Z, Zhu S. 2015. Is Huachansu beneficial in treating advanced non-small-cell lung cancer? Evidence from a meta-analysis of its efficacy combined with chemotherapy. Evid Based Complement Alternat Med. 2015:408145.
   PubMed Web of Science ®Google Scholar
• Ziv R. 2013. AKT as locus of cancer multidrug resistance and fragility. J Cell Physiol. 228:4.
   Web of Science ®Google Scholar